Press coverage about Akcea Therapeutics (NASDAQ:AKCA) has trended somewhat positive on Tuesday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.8262453159817 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Ionis Pharmaceuticals’ Royalties Rise, but So Do Expenses (msn.com)
- Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses (finance.yahoo.com)
- FDA Approves $450000-a-Year Treatment for Rare Disease (fortune.com)
- Akcea Therapeutics, Inc. (AKCA) stock returned 26.56% up – Monthly Gainer (nasdaqplace.com)
A number of research firms have recently issued reports on AKCA. UBS Group downgraded shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. BMO Capital Markets lifted their price objective on shares of Akcea Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 7th. Wells Fargo & Co lifted their price objective on shares of Akcea Therapeutics from $33.00 to $46.00 and gave the company an “outperform” rating in a report on Tuesday, August 7th. Stifel Nicolaus reiterated a “hold” rating and issued a $33.00 price objective on shares of Akcea Therapeutics in a report on Tuesday, August 7th. Finally, ValuEngine upgraded shares of Akcea Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 16th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Akcea Therapeutics presently has a consensus rating of “Hold” and an average target price of $37.00.
Akcea Therapeutics (NASDAQ:AKCA) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.04) by $0.32. Akcea Therapeutics had a negative net margin of 192.97% and a negative return on equity of 58.32%. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $14.24 million. During the same period last year, the company earned ($0.41) earnings per share. The firm’s revenue was up 221.1% compared to the same quarter last year. sell-side analysts predict that Akcea Therapeutics will post -1.91 EPS for the current fiscal year.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.
See Also: Understanding Analyst Ratings
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.